Emerald Advisers LLC lessened its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 43.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 294,402 shares of the company's stock after selling 225,712 shares during the quarter. Emerald Advisers LLC owned 0.37% of Akero Therapeutics worth $11,917,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its position in Akero Therapeutics by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock worth $15,042,000 after acquiring an additional 8,096 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Akero Therapeutics in the fourth quarter valued at about $320,000. AlphaQuest LLC grew its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after acquiring an additional 8,147 shares in the last quarter. Swiss National Bank grew its stake in shares of Akero Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 95,600 shares of the company's stock valued at $2,660,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Kennondale Capital Management LLC acquired a new position in shares of Akero Therapeutics in the fourth quarter valued at about $785,000.
Akero Therapeutics Trading Down 0.8%
NASDAQ:AKRO traded down $0.43 on Friday, reaching $51.57. 618,863 shares of the stock traded hands, compared to its average volume of 1,054,935. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -26.45 and a beta of -0.15. Akero Therapeutics, Inc. has a 1-year low of $21.34 and a 1-year high of $58.40. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The company's 50 day moving average is $49.59 and its 200-day moving average is $43.60.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $1.91. Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
AKRO has been the subject of several recent analyst reports. Bank of America upped their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Citigroup dropped their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics presently has an average rating of "Buy" and a consensus target price of $82.50.
Read Our Latest Report on Akero Therapeutics
Insiders Place Their Bets
In related news, insider Catriona Yale sold 10,000 shares of the business's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $39.30, for a total value of $393,000.00. Following the sale, the insider directly owned 95,034 shares in the company, valued at approximately $3,734,836.20. The trade was a 9.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Timothy Rolph sold 25,000 shares of Akero Therapeutics stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00. Following the transaction, the insider directly owned 169,721 shares of the company's stock, valued at $9,341,443.84. The trade was a 12.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 241,229 shares of company stock valued at $11,933,685 in the last three months. 7.07% of the stock is currently owned by insiders.
About Akero Therapeutics
(
Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Featured Articles

Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.